AVI Biopharma, Inc. - AVII- Profile

AVI BioPharma, Inc.. The Company's principal activity is to develop therapeutic products for the treatment of life-threatening diseases using third-generation NEUGENE antisense drugs. NEUGENE drugs used in treatment of cardiovascular disease, infectious disease, cancer and polymathic kidney disease (PKD), and in regulating drug metabolism. In NEUGENE antisense compounds targeting West Nile virus, Hepatitis C virus, Influenza A virus, Dengue virus, the SARS coronavirus, and Ebola virus, as well as many of the viruses included on the Department of Homeland Security list of bioterrorism agents, including Marburg, Junin, Anthrax, and Ricin. The Company has also introduced a NEUGENE-based exon-skipping technology called ESPRIT therapy. The trade marks include NEUGENE, AVICINE, Resten-NG, Resten-CP, and Oncomyc-NG. Develops therapeutic products principally based on third-generation NEUGENE antisense technology